First human test of new lung cancer drug combo completed
Disease control
Completed
This study tested the safety and side effects of a new drug, ONO-7475, when given alongside the standard drug osimertinib. It involved 78 adults with advanced or recurrent non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goal was to find a s…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co. Ltd • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC